Univariate analysis of predictive parameters for posttransplant recurrence-free long-term-survival in the IBT group (n = 59).

*<p>based on clinical staging.</p><p>PET: positron emission tomography.</p><p>G: grading.</p><p>AFP: alpha-fetoprotein.</p><p>UCSF: University of California San Francisco.</p

This figure demonstrates the micrographs (HE, 50×; 70×) of a post-IBT tumor responder with near complete postinterventional tumor necrosis (a), and of a tumor non-responder to IBT with necrotic tumor areas next to pseudoglandular HCC nodules (b), respectively.

<p>This figure demonstrates the micrographs (HE, 50×; 70×) of a post-IBT tumor responder with near complete postinterventional tumor necrosis (a), and of a tumor non-responder to IBT with necrotic tumor areas next to pseudoglandular HCC nodules (b), respectively.</p

There was no significant difference in 5-year recurrence-free survival rate between Milan In recipients (87%) and Milan Out patients demonstrating post-IBT tumor response (80%).

<p>In contrast, none of Milan Out recipients without tumor response to IBT have survived 5 years post-LT (<i>P</i><0.001).</p

Correlation of pretransplant available (clinical) parameters with tumor response to IBT (n = 59).

*<p>based on clinical staging.</p><p>PET: positron emission tomography.</p><p>AFP: alpha-fetoprotein.</p

This graph illustrates outcome stratified by Milan criteria and post-IBT tumor response.

<p>We found excellent 5-year recurrence-free survival in Milan In and Milan Out patients with postinterventional tumor response (100%/80%), compared to inferior outcome in Milan In and Milan Out recipients without extended post-IBT tumor necrosis (38,1%/0%; <i>P</i><0.001), respectively.</p

There was no significant difference in recurrence-free survival between patients receiving and those not receiving pretransplant IBT (<i>P</i> = 0.25).

<p>There was no significant difference in recurrence-free survival between patients receiving and those not receiving pretransplant IBT (<i>P</i> = 0.25).</p

Tumor recurrence rates in patients meeting and exceeding the Milan/UCSF criteria, according to IBT.

<p>UCSF: University of California San Francisco.</p

HCC with increased ¹⁸F-FDG uptake on <b><i>a</i></b> pretransplant PET scan and <b><i>b</i></b> PET-CT scan were classified as PET +.

<p>HCC with increased ¹⁸F-FDG uptake on <b><i>a</i></b> pretransplant PET scan and <b><i>b</i></b> PET-CT scan were classified as PET +.</p

Tumor responders to IBT had a significantly better 5-year recurrence-free survival probability (90%) than patients without tumor response to IBT (21%; <i>P</i><0.001).

<p>Tumor responders to IBT had a significantly better 5-year recurrence-free survival probability (90%) than patients without tumor response to IBT (21%; <i>P</i><0.001).</p

Multivariate analysis of predictive parameters for posttransplant recurrence-free survival in the IBT group (n = 59).

<p>CI: confidence interval.</p><p>HR: hazard ratio.</p